姓名：王育生性別：女政治面貌：中共黨員學(xué)歷：碩士研究生學(xué)位：博士研究生職稱：主任醫(yī)師

博、碩導(dǎo)師：博士生導(dǎo)師本崗位工作年數(shù)：5年

研究方向：消化道腫瘤發(fā)病及耐藥機(jī)制研究

榮譽(yù)稱號(hào)：百千萬(wàn)衛(wèi)生人才培養(yǎng)工程骨干精英人才

學(xué)術(shù)任職：

中國(guó)臨床腫瘤學(xué)會(huì)(CSCO)理事

國(guó)家腫瘤質(zhì)控中心胃癌質(zhì)控專家委員會(huì)委員

中國(guó)研究型醫(yī)院學(xué)會(huì)腫瘤學(xué)專委會(huì)常委

北京癌癥防治學(xué)會(huì)食管癌專委會(huì)常委

CSCO胰腺癌專委會(huì)、 胃腸間質(zhì)瘤專委會(huì)、臨床研究專委會(huì)委員

CACA整合腫瘤腎臟病專委會(huì)、食管腫瘤整合康復(fù)專委會(huì)常委

CACA腫瘤肝臟病學(xué)專委會(huì)、MDT專委會(huì)、信息化管理專委會(huì) 委員

山西省抗癌協(xié)會(huì)腫瘤異質(zhì)性與個(gè)體化治療委員會(huì)主任委員

山西省老年醫(yī)學(xué)學(xué)會(huì)腫瘤整合醫(yī)學(xué)分會(huì)會(huì)長(zhǎng)

山西省醫(yī)師協(xié)會(huì)肝病醫(yī)師分會(huì)肝癌學(xué)組組長(zhǎng)

山西省抗癌協(xié)會(huì)腫瘤臨床試驗(yàn)專委會(huì)、食管癌專委會(huì)、腫瘤胃腸病學(xué)專委會(huì)、腫瘤整體評(píng)估專委會(huì)副主任委員

山西省醫(yī)師協(xié)會(huì)肝病醫(yī)師分會(huì)青委會(huì)副主任委員

山西省健康管理學(xué)會(huì)健康教育專委會(huì)副主任委員

山西省老年醫(yī)學(xué)學(xué)會(huì)胃腸間質(zhì)瘤分會(huì) 、 臨床營(yíng)養(yǎng)分會(huì)副會(huì)長(zhǎng)

近五年承擔(dān)科研課題情況：

(1)山西省衛(wèi)健委,“四個(gè)一批”科技興醫(yī)創(chuàng)新計(jì)劃項(xiàng)目重點(diǎn)攻關(guān)項(xiàng)目, 2023XM024, KRAS分子分型指導(dǎo)下的晚期胰腺癌精準(zhǔn)診療方案研究與驗(yàn)證, 2023-09至2025-08, 15萬(wàn)元,在研,主持

(2)北京科創(chuàng)基金項(xiàng)目,基礎(chǔ)研究, KC2021-JX-0186-104,通過(guò)阻斷PD- 1/PD-L1和P38MAPK雙通路達(dá)到抗MSS型結(jié)腸癌細(xì)胞增殖的研究, 2022-06至2024-06, 15萬(wàn)元,結(jié)題,主持

(3)山西省衛(wèi)健委,基礎(chǔ)研究, 2022025,阻斷P38MAPK信號(hào)通路逆轉(zhuǎn)胃癌治療中PD-1抑制劑耐藥的機(jī)制研究, 2022-01至2024-01, 3萬(wàn)元,結(jié)題,主持

代表性論著及近五年的代表性論文（限10項(xiàng)以內(nèi)）：

1、Meng Qianhao^1?, Zhao Jian^2?, Yu Yuanyuan^1?, Wang Ke¹, Ren Jing¹,Xu Chang¹,Wang Yusheng^2*and Wang Guangyu^1*,Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study [J]. BMC Cancer, 2023, 23(1): 191.

2、Zhu Xiao-Dong^1,2,?,Huang Ming-Zhu^1,2,?,Wang Yu-Sheng^3,?,Feng Wan-Jing^1,2,?,Chen Zhi-Yu^1,2,?,He Yi-Fu^4,?,Zhang Xiao-Wei^1,2,Liu Xin^1,2,Wang Chen-Chen^1,2,Zhang Wen^1,2,Ying Jie-Er⁵,Wu Jun⁶,Yang Lei⁷,Qin Yan-Ru⁸,Luo Jian-Feng⁹,Zhao Xiao-Ying^1,2,Li Wen-Hua^1,2,Zhang Zhe^1,2,Qiu Li-Xin^1,2,Geng Qi-Rong^1,2,Zou Jian-Ling^1,2,Zhang Jie-Yun^1,2,Zheng Hong¹⁰,Song Xue-Feng³,Wu Shu-Sheng⁴,Zhang Cheng-Yan³,Gong Zhe^1,2,Liu Qin-Qin^1,2,Wang Xiao-Feng⁸,Xu Qi⁵,Wang Qi⁶,Ji Jian-Mei⁷,Zhao Jian³,Guo Wei-Jian^1,2,XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX) [J]. Cancer Commun (Lond), 2022, 42(4): 314-326.

3、Zhang Ninggang^1?, Ren Yaqiong^2?, Zan Likun³, Zhang Xuting⁴, Jian Zhao¹, Wen Lu¹andWang Yusheng^1*,Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor [J]. Front Oncol, 2022, 12:966818.

4、Tian Zhihui, Zhao Jian,Wang Yusheng,The prognostic value of TPM1-4 in hepatocellular carcinoma [J]. Cancer Med, 2022, 11(2): 433-446.

5、Rong Xuetong¹, Liu Haiyi², Yu Hongmei¹, Zhao Jian²,Wang Jie¹,Wang Yusheng²,Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer [J]. Invest New Drugs, 2022, 40(2): 340-348.

6、Yu Penngfei,^a,?Wang Yusheng,^b,?Yu Yanfei,^cWang aodi,^cHuang Ling ,^aZhang Yuan ,^cLiu Wenjing,^cWu Haiyan,^cYao Ming ,^cDu Yi-an ,^aCheng Xiangdong^a,Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma [J]. Oncologist, 2021, 26(5): e756-e768.

7、Wang Yusheng,¹Shang Kun,¹Zhang Ninggang,²Zhao Jian,²and Cao Bangwei^1,i,Tumor-Associated Macrophage-Derived Exosomes Promote the Progression of Gastric Cancer by Regulating the P38MAPK Signaling Pathway and the Immune Checkpoint PD-L1 [J]. Cancer Biother Radiopharm, 2021: Oct 25.

8、Wang Yusheng^1,2, Zhao Jian², Yu Hongmei³, Wang Jie⁴, Zhang Ninggang², Cao Bangwei¹,Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma [J]. J Cancer Res Ther, 2021, 17(5): 1234-1240.

9、Wang Jie,¹Xi Yanfeng,²Zhao Jian,³Rong Xuetong,¹Lu Weidong,¹andWang Yusheng³,The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients [J]. Gastroenterol Res Pract, 2021, 2021: 4269781.

10、Huang Mingzhu^1,2,Yang Yue^1,2,Zhu Xiaodong^1,2,Chen Zhiyu^1,2,Zhang Wen^1,2,Wang Chenchen^1,2,Zhang Xiaowei^1,2,Qiu Lixin^1,2,Zhang Zhe^1,2,Zhao Xiaoying^1,2,Li Wenhua^1,2,Wang Yusheng³,Guo Weijian^1,2,A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer[J]. Asia Pac J Clin Oncol, 2021, 17(6): 513-521.